Background: 1,3-b-D-Glucan (BDG) is a fungal cell wall constituent used in the diagnosis of invasive fungal infections. BDG testing, although endorsed by the European Organization for Research and Treatment of Cancer, suffers from limited specificity. False-positive results have been linked to haemodialysis membranes, blood products, antineoplastic agents and antimicrobial use.
Introduction
1,3-b-D-Glucan (BDG), like galactomannan, is a fungal cell well constituent used to establish the diagnosis of invasive fungal infections (IFIs) in accordance with official guideline criteria. 1, 2 In analogy to galactomannan, 3 it has a known potential for falsepositive results correlated to e.g. haemodialysis, blood product transfusion and wound gauze. 4 -6 The correlation of false-positive BDG results with antibiotic exposure in haematology/oncology patients 7 is especially alarming, as high-risk patients are very likely to have received antibiotic therapy prior to attempts to diagnose an IFI. Indeed, persistent fever despite broad-spectrum antibiotic treatment is a major indicator of IFI. 8 To examine an underlying causality for this observed correlation, we measured BDG in 30 routinely used antibiotics, as well as 5 antifungals.
Materials and methods
All antimicrobial substances were obtained through the pharmacy of the University Clinic of Cologne. The drugs were freely sold, unspoiled and fit for intravenous administration. Samples were either ready-to-use infusion solutions or lyophilized powders. The powders were reconstituted according to the manufacturer's instructions using glucan-free (,1 pg/mL BDG) instruments and reagents. Investigational products and topical or oral drugs were excluded from the analysis.
The antimicrobial substances were tested for their respective BDG content using two different BDG tests [Fungitell assay (Associates of Cape Cod, MA, USA) and BioAssay (United States Biological, Salem, MA, USA)] according to the instructions of the respective manufacturer. Briefly, for the Fungitell assay, 5 mL of the drug was pretreated with 20 mL of alkaline reagent, incubated with 100 mL of Fungitell reagent at 378C and monitored at 405 nm kinetically for 40 min. For the BioAssay, 100 mL of the drug was treated with 10 mL of balance solution and incubated with 50 mL of enzyme conjugate for 1 h at 378C followed by incubation with 50 mL of substrates A +B for 15 min at room temperature. Absorbance was measured at 450 nm after the addition of 50 mL of stop solution. All tests were run in triplicate using glucan-free (,1 pg/mL BDG) pipette tips and reagents.
Results and discussion
Of the tested antimicrobials, 25 contained sufficient amounts of BDG to cause a positive assay result ( Table 1 ). The strength of this study lies in analysing a broad cross-section of commonly used antimicrobials. However, the resulting data need to be interpreted cautiously as only samples from a single batch were analysed for most drugs and BDG concentrations may fluctuate between batches, as well as manufacturers, as seen with cefazolin (Table 1 ). This variation in BDG contamination between manufacturers and batches may explain the discrepancy between our findings and prior reports of minimal BDG amounts in antimicrobials. 9 Among other factors, the contamination of most antimicrobial substances with BDG may contribute to the limited usefulness of BDG testing in patients with prior exposure to antibiotics or antifungals. This finding may also partially explain the variability of previously suggested positivity cut-offs, as patients exposed to varying amounts of BDG through infusion solutions may exhibit varying BDG levels even in the absence of a fungal infection. A burdensome approach would be to establish an individual positivity cut-off for each patient based on the amount of BDG infused and then adjust for the plasma kinetics of BDG. 10 In the face of possible immunomodulatory properties of BDG, 11 an intervention to reduce contamination on the manufacturing side should be considered. The feasibility of such an intervention has been recently demonstrated for 'galactomannan-containing' piperacillin/tazobactam. 12 If adjusting the manufacturing process to reduce contamination, e.g. through eliminating cellulose membranes, is not immediately possible, the BDG content could be declared in the package leaflet. At least in the EU, regulatory statutes may actually require such a declaration (e.g. under Title V, Article 54, EU Directive 2001/83/EC). Values shown in bold are above the positivity cut-off.
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